Organic Active Ingredients TRIZ Cases

Modifying nucleoside structures enhances antiviral activity against HBV, HCV, and SARS-CoV2 while addressing cancer cell proliferation.

Self-foaming clobetasol propionate composition eliminates skin irritation from surfactants while enabling rapid, wide-area coverage for psoriasis treatment.

Structural modifications enhance aqueous solubility of CaMKK2 inhibitors, enabling effective topical delivery for treating ocular inflammatory diseases.

A transdermal patch delivers naltrexone via a cross-linked polyethylene oxide hydrogel matrix.

A non-radioactive immunoassay detects 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine using enzyme-conjugated antibodies.

Ligands target the JAK2 pseudokinase domain to treat myeloproliferative disorders with reduced side effects.

Genome engineering tools edit the BCL11A gene to modulate fetal hemoglobin expression.

A chitosan pharmaceutical composition forms a protective film on wounds to sustain drug delivery and accelerate healing.

A nutritional supplement composition strengthens pelvic floor muscles and reduces urinary urgency through synergistic ingredient action.

Treating fat with rosemary suppresses peroxide formation and unpleasant odors while maintaining low water content.

Pyrimidine amide compounds inhibit prostaglandin D synthase to treat nasal congestion unaddressed by antihistamines.

Flibanserin addresses inadequate hormonal treatments by reducing hot flashes across naturally occurring and surgically induced menopause types.

Alginate salts create a physical barrier preventing esophageal acid exposure without systemic absorption.

A series of improved processes involving acylation, Grignard reactions, Suzuki coupling, and hydrolysis steps to produce the target compound.

Effervescent tablets dissolve in water to enable rapid transmucosal absorption, bypassing gastrointestinal degradation and needle fears.

Novel agmatinase inhibitor compound regulates excitatory and inhibitory neuron balance to address social impairment and hyperactivity.

Modified autotaxin inhibitors reduce lysophosphatidic acid levels while improving pharmacokinetic properties for central nervous system treatments.

Trisubstituted benzotriazole derivatives inhibit dihydroorotate dehydrogenase to treat autoimmune disorders and cancers.

Administering arginine silicate inositol prevents myopathies like white striping while maintaining feed efficiency.

Sulphate salts of a piperazine-imidazole compound resolve oxalate nephrotoxicity while ensuring stability and crystallinity.

Monoclonal antibodies target MFAP5 to inhibit cancer cell invasion and suppress microvessel formation.

Small molecule isoindole derivatives replace complex protein therapies to lower manufacturing costs while maintaining therapeutic efficacy.

Segmented scaffold design with modular substituents inhibits SHP2 activity while managing synthesis complexity for targeted disease treatment.

Inhibitory nucleic acids targeting microRNA 33 reduce triglyceride levels and improve metabolic health by enhancing mitochondrial fatty acid beta-oxidation.

Short antisense compounds reduce target RNA with high potency, lowering toxicity and treatment costs.

Antibody-mediated delivery of ALK5 inhibitors to fibrotic tissues minimizes systemic toxicity while inhibiting tumor progression.

Formula I compounds inhibit wild-type and mutant NTRK kinases, resolving resistance from intrinsic mutations while reducing off-target toxicities.

Consensus framework predicts compound-viral protein activity using deep learning embeddings.

Substituted bicyclic dihydropyrimidinones inhibit neutrophil elastase while resolving the contradiction between inhibitory potency and metabolic stability.

A cyclic dinucleotide prodrug molecule uses a phosphotriester protecting group to cross cell membranes and release active drug.

A novel amine derivative inhibits keratinocyte proliferation and TNF-alpha production to treat skin diseases.

Crospovidone mediates the matrix to protect the derivative from oxidation during long-term storage.

Orthogonal packaging sites enable a phagemid cocktail to target diverse bacterial strains and reduce resistance risks.

2,4,5-substituted pyrimidine compounds inhibit focal adhesion kinase with high selectivity over other protein kinases.

Albumin-bound paclitaxel nanoparticles overcome drug resistance in BRAF-mutant melanoma, extending progression-free survival.

A topical skin care composition containing tetracaine and beeswax reduces pain and inflammation while promoting healing.

Bicyclic heteroaromatic ring compounds inhibit picornavirus replication, addressing the lack of effective treatments for rhinovirus infections.

A hyaluronan conjugate blocks the IL-6-mediated cascade to reduce pulmonary inflammation.

Modular pyrazolo[1,5-a]pyrazine scaffolds achieve subtype selectivity for mGluR2 and mGluR3 despite synthesis complexity.

Quinoxaline derivatives target cancer cell kinases via local quality and parameter changes, reducing toxicity to healthy cells.

Dual H1 inverse agonist and 5-HT2A antagonist compounds achieve selective receptor binding to improve sleep maintenance while minimizing off-target effects.

Water-mediated crystallization yields high-purity dapagliflozin hydrate, eliminating organic solvent impurities and boosting bioavailability.

CRISPR/Cas9 system knocks out the mutant NR2E3 allele via non-homologous end joining to treat autosomal dominant retinitis pigmentosa.

A non-viral gene carrier complex delivers shRNA to visceral adipose tissue macrophages.

A phosphate buffered saline and oil medium system stabilizes n-butylidenephthalide for intranasal delivery.

A hepatitis B vaccine formulation combines surface antigen with unmethylated CpG motifs to elicit seroprotective antibody responses.

Sodium bicarbonate in the infusion corrects acidosis to prevent hypothermia and speed recovery.

Vaginal DHEA suppositories deliver precursors to treat atrophy without raising estradiol levels.

A calcium bolus combines rapidly absorbable salts with a 1-alpha hydroxylated vitamin D compound to stimulate intestinal transport.

Pyrimido-pyrimidine derivatives reduce apnea-hypopnea index by increasing upper airway responses without affecting minute ventilation.

Cleavable linkers maintain extracellular stability while releasing cytotoxic pyrrolobenzodiazepine compounds intracellularly to reduce systemic toxicity.

Novel heteroaryl derivatives activate soluble guanylate cyclase to raise cGMP levels, avoiding tolerance associated with organic nitrates.

L-Ergothioneine attenuates age-related muscle mass loss by improving ATP production and blocking chronic reactive oxygen species.

Nujiangexanthone A selectively targets Syk phosphorylation, reducing cytokine production and mast cell degranulation for precise asthma therapy.

Novel benzimidazole-carboxamide compounds act as potent 5-HT4 receptor agonists with high selectivity.

One-pot synthesis eliminates intermediate isolation to reduce production time and waste while achieving high purity.

RAD51 enhancer component stimulates interchromosomal homologous recombination to resolve controversial reliability of heterozygous mutation correction.

Prexasertib combined with anti-PD-1 overcomes low glioma response rates by increasing tumor susceptibility to T-cells.

A kinked amphipathic peptide with an N-terminal fatty acid loosens bacterial membranes to enhance antibiotic penetration.

Compounds of Formula (I A), (I B), and (I D) inhibit PRMT5 activity to treat proliferative, metabolic, and blood disorders.

Selective S-enantiomer 2-arylpropionic acid derivatives inhibit CXCL8-induced neutrophil chemotaxis, reducing tissue damage in ischemia and inflammation.

Gene expression analysis characterizes hidradenitis suppurativa severity, resolving diagnostic delays and enabling stage-specific therapy.

A diltiazem hydrochloride gel formulation uses propylene glycol and benzoic acid to create a stable semi-solid dosage form.

Fluorinated compounds embedded in contact lenses resist lipid and protein deposition while maintaining optical transparency.

A migraine aura formulation combining Tanacetum parthenium extract, magnesium cations, and 5-hydroxy-tryptophan to target multiple pathogenic mechanisms.

Structural engineering of compounds extracts unstable water from the TYK2 binding pocket, resolving insufficient potency in autoimmune treatments.

Compound 1 targets the specific BTK enzyme pathway to improve complete remission rates while reducing treatment side effects.

Reversible non-covalent FXIIa inhibitors maintain potency while reducing off-target cytotoxicity.

A pressure-compensated cutter assembly uses a movable piston to balance lubricant pressure against external hydrostatic forces.

Target sequences with high human genome similarity interact with viral RNA to activate inflammatory factors, addressing vaccine stability challenges.

Blocking pregnenolone metabolism via C3 methoxy modification eliminates adverse effects while reducing excessive alcohol consumption.

Cationic steroid antimicrobials promote osteogenesis via gene modulation, resolving limited bone growth effectiveness in standard treatments.

Distinct polymorphic forms of the indazole compound improve dissolution rates and reduce impurities, ensuring consistent formulation reliability.

Amino acid-modified NOTA compounds chelate intracellular copper ions with high specificity, reducing toxicity compared to existing agents.

Structural optimization of heterocyclic compounds enhances receptor modulation effectiveness while minimizing psychoactive side effects.

Topical phosphosulindac reduces neuronal signaling, avoiding systemic side effects while treating diabetic peripheral neuropathy pain.

DARICs employ dimerizing agents to control immunoreceptor activation, mitigating cytokine release syndrome risks while targeting CD33.

A magnetic anion exchange matrix selectively binds short nucleic acids via electrostatic interactions.

Macrocyclic compounds constrain PD-1 and CD80 binding interfaces, restoring T-cell function while reducing treatment complexity.

Bivalent compounds degrade EZH2 protein via ubiquitin-proteasome recruitment, overcoming resistance from stable enzyme levels in breast cancer.

Segmented molecular structures optimize binding affinity while managing synthesis complexity.

Spray dried alginate oligomer particles incorporate phospholipids to reduce hydrophilicity and enable lung delivery.

Mesoporous silica particles loaded with poorly soluble drugs feature polymer solid dispersion coatings.

Novel 5-carbamoyl-adamantan-2-yl amide derivatives selectively inhibit 11β-HSD1 enzyme activity.

An intra-oral light therapy apparatus emits controlled light to alveolar soft tissue to accelerate orthodontic tooth movement.

Ternary co-amorphous forms combine drugs, proteins, and polymers to overcome insufficient solubility enhancement found in binary systems.

An artificial diet composition restricts essential amino acids to selectively kill cancer cells.

A biodegradable implant releases TMC278 via diffusion and degradation to maintain steady plasma levels.

Administering a PTP1B inhibitor targets the IL13/IL13Rα2 pathway to reduce tumor growth and improve survival in glioblastoma models.

A biomarker panel measures polypeptide levels to classify chronic lymphocytic leukemia subtypes.

Embelin eliminates resistant polyploid cancer cells to prevent tumor relapse after standard therapy.

pH-dependent lipid matrix releases capsaicinoids in the small intestine, reducing stomach discomfort and production costs.

15β-substituted estradiol derivatives target estrogen receptor alpha subtypes, reducing endometrial proliferation and breast cancer risk in long-term therapy.

Tolerizing agents modulate TIM family receptors to induce antigen-specific immune tolerance, mitigating unwanted responses to enzyme and gene therapies.